Clifford J Bailey, EASD 2019: Heart failure and diabetes

(7:49)

John Doupis, EASD 2019: How can we simplify treatment decisions?

(3:24)

How was it for you? The experts discuss EASD 2019 | John Wilding, Amrit Lamba, and Lori Berard

(22:8)

EASD 2019 Highlights from Medscape

(1:32)

EASD 2019 : Personalised Prevention Of CVD In T2D- Prof Alessandro Doria

(5:12)

Tina Vilsbøll, EASD 2019 - Cardiorenal risk in type 2 diabetes

(5:32)

EASD 2019 Juan Jose Gagliardino

(5:)

Ann Marie Navar, EASD 2019: Safety profile of PCSK9 inhibitors

(6:23)

A Real World Approach to LDL cholesterol using PCSK9 inhibitors, October 5 2018

(52:4)

September Diabetes Technology Report EASD 2019, Diabetes Drones, Smart Pens and more

(6:26)

Professor Cliff Bailey - 'Is there still a place for sulphonylureas?'

(36:50)

EASD 2019 : CREDENCE Trial - Prof Carol Pollock

(10:20)

Teneligliptin is Better than Sitagliptin Among the DPP4 Inhibitors | Dr. Ashish Rohatgi

(6:31)

EASD 2022 Discussion about newer therapies by Dr Stefano Del Prato Italy \u0026 Dr Benny Negalur India

(10:48)

PCSK9 Inhibition: Lowering Lipids and Reducing Cardiovascular Events

(1:5:30)

ESC TV at ESC Congress 2019 - 2019 ESC/EAS Guidelines on Dyslipidaemias

(3:5)

AASLD Liver Meeting 2019 Highlights

(58:43)

Steve Bain, EASD 2019: Oral GLP-1 receptor agonist and semaglutide

(6:33)

EASD 2019 John Buse

(6:47)

Michael Stumvoll, EASD 2019: VERIFY Study results

(6:51)

EASD 2019 Michael Trautmann

(4:26)

EASD 2019 Gaurav Verma

(12:45)

EASD 2019 Mariangela Gaudio

(6:3)

Umar Wahab, EASD 2019: The prevalence of diabetes in Pakistan (Part 1)

(6:44)

Clifford J Bailey, EASD 2019: Results of the VERIFY study

(4:19)

John Soupal, EASD 2019: The COMISAIR study

(4:59)

EASD 2019 Erik van Poelgeest

(4:14)

Luis Masana Marín, EASD 2019: PCSK9 Inhibition in Clinical Practice

(6:51)

EASD 2019 360° Yong Ho Lee

(6:23)

EASD 2019 Interview with Stefano Del Prato

(8:30)